A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive Controlled Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Alios BioPharma; Janssen Research & Development
- 29 Jun 2017 Status changed from recruiting to completed.
- 31 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 Feb 2017.
- 31 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Feb 2017.